We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference
News

MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference

MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference
News

MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "MDxHealth CEO to Keynote at Biomarkers from Research to Clinic Conference"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

MDxHealth SA has announced that its CEO, Dr Jan Groen, will deliver a keynote presentation at the Biomarkers from Research to Clinic, Prognostic, Predictive & Point-of-Care Conference at 13:15 PST on January 15 in San Diego, CA, USA.

The presentation, "Epigenetic Biomarkers in Oncology", will highlight the development and commercialization of epigenetic diagnostic tests, several of which are now commercially available and used routinely in clinical practice. 

All cancers show epigenetic changes. Measuring the epigenetic changes associated with specific genes can help guide physicians in the management of a patient's disease.  With continued market adoption of the ConfirmMDx® for Prostate Cancer test, the inclusion of PredictMDx® for Glioblastoma into the NCCN guidelines, and the launch of Cologuard® for colon cancer by licensee Exact Sciences, there are now three successful diagnostic tests on the U.S. market using MDxHealth's epigenetic technology and biomarkers. 


Advertisement